Sector News

Valeant board debating Pearson's return as health improves: CNBC

February 26, 2016
Life sciences

The health of Valeant Pharmaceuticals International Inc’s Michael Pearson is improving, the company said on Thursday, but CNBC reported that there was debate within the board over whether he was ready to return to work.

Pearson, who joined Valeant as chief executive in 2010, was hospitalized with severe pneumonia in late December.

The company named former Chief Financial Officer Howard Schiller as interim CEO in January.

CNBC, citing a source, said Pearson was ready to return but the board was debating whether he should. (bit.ly/20X0uU8)

(Reporting by Natalie Grover in Bengaluru; Editing by Ted Kerr)

Source: Reuters

Related News

May 8, 2021

BD to spin off $1B diabetes care business into standalone public company

Life sciences

BD’s new company will have the freedom to expand its portfolio of tools and technologies for the chronic care of diabetes.

May 8, 2021

Galapagos cuts pipeline, targets €150M in savings after setbacks

Life sciences

The Belgian biotech is pulling out of metabolic diseases and osteoarthritis R&D to focus on its core therapeutic areas.

May 8, 2021

Catalent snares yet another Belgian CDMO to boost fast-growing cell and gene therapy campus

Life sciences

Catalent will use its new facility for commercial production of plasmid DNA, used to make a range of biologics, including viral vectors, mRNA and cell therapies.

Send this to a friend